Loading...
•
Mar 31, 2020
Surmodics Q2 2020 Earnings Report
Surmodics reported a 1% increase in revenue year-over-year and GAAP EPS of $0.11.
Key Takeaways
Surmodics, Inc. reported a slight increase in revenue for the second quarter of fiscal year 2020, with a 1% increase year-over-year. GAAP EPS was $0.11, while non-GAAP EPS was $0.04. The company has suspended its financial guidance for fiscal year 2020 due to the uncertainty surrounding the COVID-19 pandemic.
Total revenue for the second quarter of fiscal 2020 was $22.8 million, compared to $22.7 million in the prior-year period.
GAAP EPS was $0.11, while non-GAAP EPS was $0.04.
Medical Device revenue was $16.3 million, a decrease of 6% year-over-year, impacted by patent expiration and COVID-19 related procedure postponements.
In Vitro Diagnostics revenue was $6.5 million, an increase of 21% year-over-year.
Revenue by Segment
Forward Guidance
Due to the uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, Surmodics is suspending the previously issued financial guidance for fiscal year 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...